Alphabet Inc. — 13F Holdings & Portfolio
CIK 1652044 · latest 13F-HR filed 2026-05-08
Alphabet Inc. manages $4.02B in 13F-reported U.S. long-equity assets across 27 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are CME (25.63%), PL (24.53%), ASTS (18.46%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 3 new positions, exited 6, added to 6, and trimmed 13.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$4.02B
Long-equity book
27
Distinct positions
2026-03-31
Filed 2026-05-08
+3 / −6 / ↑6 / ↓13
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- PLANET LABS PBC$355.3M +56.4%
- AST SPACEMOBILE INC$91.6M +14.1%
- ARM HOLDINGS PLC$82.3M +38.4%
- REVOLUTION MEDICINES INC$53.8M +20.2%
- RELAY THERAPEUTICS INC$2.3M +17.3%
Top Trims
- FRESHWORKS INC-$68.4M -34.4%
- GITLAB INC-$43.3M -42.3%
- UIPATH INC-$37.2M -32.3%
- TEMPUS AI INC-$21.5M -23.4%
- MAZE THERAPEUTICS INC-$16.1M -28.0%
Exited Positions
- DEXCOM INC$68.8M
- GENEDX HOLDINGS CORP$3.0M
- EXACT SCIENCES CORP$2.4M
- QUINCE THERAPEUTICS INC$633.6K
- FULCRUM THERAPEUTICS INC$161.3K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CME GROUP INC | CME | 12572Q105 | $1.03B | 25.63% | 3,484,020 | SH |
| 2 | PLANET LABS PBC | PL | 72703X106 | $985.2M | 24.53% | 35,248,893 | SH |
| 3 | AST SPACEMOBILE INC | ASTS | 00217D100 | $741.1M | 18.46% | 8,943,486 | SH |
| 4 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $320.2M | 7.97% | 3,292,525 | SH |
| 5 | ARM HOLDINGS PLC | ARM | 042068205 | $296.6M | 7.39% | 1,960,784 | SH |
| 6 | FRESHWORKS INC | FRSH | 358054104 | $115.0M | 2.87% | 14,327,273 | SH |
| 7 | UIPATH INC | PATH | 90364P105 | $78.1M | 1.94% | 7,034,337 | SH |
| 8 | TEMPUS AI INC | TEM | 88023B103 | $70.1M | 1.75% | 1,551,102 | SH |
| 9 | PAYPAY CORP | PAYP | 70450C101 | $66.7M | 1.66% | 3,125,000 | SH |
| 10 | GITLAB INC | GTLB | 37637K108 | $59.0M | 1.47% | 2,724,712 | SH |
| 11 | PRIME MEDICINE INC | PRME | 74168J101 | $57.6M | 1.44% | 16,562,498 | SH |
| 12 | ETHOS TECHNOLOGIES INC | LIFE | 29765A101 | $42.1M | 1.05% | 3,770,156 | SH |
| 13 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $41.4M | 1.03% | 1,388,583 | SH |
| 14 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $25.3M | 0.63% | 2,823,126 | SH |
| 15 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $15.6M | 0.39% | 1,564,173 | SH |
| 16 | FRESHWORKS INC | FRSH | 358054104 | $15.1M | 0.38% | 1,879,370 | SH |
| 17 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $11.3M | 0.28% | 684,275 | SH |
| 18 | VERA THERAPEUTICS INC | VERA | 92337R101 | $9.7M | 0.24% | 241,264 | SH |
| 19 | SANA BIOTECHNOLOGY INC | SANA | 799566104 | $8.1M | 0.20% | 2,812,500 | SH |
| 20 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $7.7M | 0.19% | 321,604 | SH |
| 21 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $5.9M | 0.15% | 293,256 | SH |
| 22 | OSCAR HEALTH INC | OSCR | 687793109 | $5.5M | 0.14% | 481,988 | SH |
| 23 | FIGMA INC | FIG | 316841105 | $4.6M | 0.11% | 215,582 | SH |
| 24 | SPERO THERAPEUTICS INC | SPRO | 84833T103 | $2.1M | 0.05% | 889,979 | SH |
| 25 | HYPERFINE INC | HYPR | 44916K106 | $970.6K | 0.02% | 898,720 | SH |
| 26 | AUTOLUS THERAPEUTICS PLC | AUTL | 05280R100 | $963.6K | 0.02% | 698,262 | SH |
| 27 | TENAYA THERAPEUTICS INC | TNYA | 87990A106 | $631.8K | 0.02% | 915,705 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-08 | $4.02B | 27 | 0001652044-26-000051 |
| 2025-12-31 | 2026-02-13 | $2.58B | 32 | 0001652044-26-000023 |